Mechanism-specific antiarrhythmic effects of the potassium channel activator levcromakalim against repolarization-dependent tachycardias
The hypothesis that levcromakalim, a potassium channel (IK-ATP) activator with antihypertensive properties, has a mechanism-specific antiarrhythmic action against repolarization-dependent ventricular tachycardias (VTs) was tested in dogs. A low dose of levcromakalim (0.01 mg/kg) was selected, which...
Saved in:
Published in | Journal of cardiovascular electrophysiology Vol. 5; no. 9; p. 731 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.09.1994
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The hypothesis that levcromakalim, a potassium channel (IK-ATP) activator with antihypertensive properties, has a mechanism-specific antiarrhythmic action against repolarization-dependent ventricular tachycardias (VTs) was tested in dogs.
A low dose of levcromakalim (0.01 mg/kg) was selected, which decreased blood pressure by 25% but had almost no electrophysiologic effect on AV nodal or ventricular conduction or effective refractory period. In dogs with chronic AV block, the antiarrhythmic action of this dose of levcromakalim was evaluated in three models of abnormal impulse formation: (1) d-sotalol (2 mg/kg) induced torsades de pointes VT, initiated by early afterdepolarizations (EADs), (2) sustained ouabain-induced VTs, which are dependent on delayed afterdepolarizations (DADs), and (3) VT occurring 24 hours after left anterior descending coronary artery occlusion, which are likely based on abnormal automaticity. Levcromakalim abolished d-sotalol induced U waves, ventricular ectopic beats, and self-terminating bouts of torsades de pointes. Induction of torsades de pointes by pacing was also completely prevented. The cycle length of the idioventricular rhythm, which was lengthened after d-sotalol from 1490 +/- 515 to 1700 +/- 610 msec (P < 0.05), remained similar after levcromakalim (1655 +/- 580 msec). The QT(U) duration, which was increased after d-sotalol from 410 +/- 55 to 550 +/- 40 msec (P < 0.05), normalized to 405 +/- 70 msec (P < 0.05). Levcromakalim did not suppress but rather enhanced ouabain-induced VT by decreasing the cycle length slightly from 315 +/- 35 to 290 +/- 35 msec (P < 0.05). Pretreatment with a beta blocker prevented this acceleration in rate. Finally, levcromakalim had no effect on VT 24 hours after infarction.
A low dose of levcromakalim has specific antiarrhythmic properties against repolarization-dependent arrhythmias, but it does not affect VTs based on other mechanisms of abnormal impulse formation. |
---|---|
AbstractList | The hypothesis that levcromakalim, a potassium channel (IK-ATP) activator with antihypertensive properties, has a mechanism-specific antiarrhythmic action against repolarization-dependent ventricular tachycardias (VTs) was tested in dogs.
A low dose of levcromakalim (0.01 mg/kg) was selected, which decreased blood pressure by 25% but had almost no electrophysiologic effect on AV nodal or ventricular conduction or effective refractory period. In dogs with chronic AV block, the antiarrhythmic action of this dose of levcromakalim was evaluated in three models of abnormal impulse formation: (1) d-sotalol (2 mg/kg) induced torsades de pointes VT, initiated by early afterdepolarizations (EADs), (2) sustained ouabain-induced VTs, which are dependent on delayed afterdepolarizations (DADs), and (3) VT occurring 24 hours after left anterior descending coronary artery occlusion, which are likely based on abnormal automaticity. Levcromakalim abolished d-sotalol induced U waves, ventricular ectopic beats, and self-terminating bouts of torsades de pointes. Induction of torsades de pointes by pacing was also completely prevented. The cycle length of the idioventricular rhythm, which was lengthened after d-sotalol from 1490 +/- 515 to 1700 +/- 610 msec (P < 0.05), remained similar after levcromakalim (1655 +/- 580 msec). The QT(U) duration, which was increased after d-sotalol from 410 +/- 55 to 550 +/- 40 msec (P < 0.05), normalized to 405 +/- 70 msec (P < 0.05). Levcromakalim did not suppress but rather enhanced ouabain-induced VT by decreasing the cycle length slightly from 315 +/- 35 to 290 +/- 35 msec (P < 0.05). Pretreatment with a beta blocker prevented this acceleration in rate. Finally, levcromakalim had no effect on VT 24 hours after infarction.
A low dose of levcromakalim has specific antiarrhythmic properties against repolarization-dependent arrhythmias, but it does not affect VTs based on other mechanisms of abnormal impulse formation. |
Author | Lipcsei, G C Vos, M A Leunissen, J D Wellens, H J De Groot, S H Gorgels, A P |
Author_xml | – sequence: 1 givenname: M A surname: Vos fullname: Vos, M A organization: Department of Cardiology, University Hospital, Maastricht, The Netherlands – sequence: 2 givenname: A P surname: Gorgels fullname: Gorgels, A P – sequence: 3 givenname: G C surname: Lipcsei fullname: Lipcsei, G C – sequence: 4 givenname: S H surname: De Groot fullname: De Groot, S H – sequence: 5 givenname: J D surname: Leunissen fullname: Leunissen, J D – sequence: 6 givenname: H J surname: Wellens fullname: Wellens, H J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/7827712$$D View this record in MEDLINE/PubMed |
BookMark | eNotkMtOwzAURL0oKqXwCUgW-wQ7tvNYooqXVMQG1tWNfU1cEiey3YryBXw2RXSk0egsZhZzQWZ-9EjIDWc5P-p2m3MlWVbzssp508g8tYzzpsy_ZmTBmVSZqCtxTi5i3DLGRcnUnMyruqgqXizIzwvqDryLQxYn1M46TcEnByF0h9QNR0RrUadIR0tTh3QaE8TodgP9K3rsKejk9pDGQHvc6zAO8Am9Gyh8gPMx0YDT2ENw35Dc6DODE3qDPtEEujtoCMZBvCRnFvqIV6dckveH-7fVU7Z-fXxe3a0zLVnFMyEkk0UjlGxMxawojlwIobnQoEoAblVdojIttEcbiUrVosXKltYWhtliSa7_d6ddO6DZTMENEA6b0yPFL1vKajM |
CitedBy_id | crossref_primary_10_1111_j_1540_8159_1999_tb00516_x crossref_primary_10_1007_BF01747188 crossref_primary_10_1016_j_jacc_2006_05_048 crossref_primary_10_1016_S0735_1097_97_00333_1 crossref_primary_10_1111_j_1540_8167_2000_tb00337_x crossref_primary_10_1097_00005344_199902000_00006 crossref_primary_10_1161_01_CIR_91_3_864 crossref_primary_10_1016_j_ijcard_2003_04_018 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1111/j.1540-8167.1994.tb01196.x |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology Biology |
ExternalDocumentID | 7827712 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .3N .GA .GJ .Y3 04C 05W 0R~ 10A 1OB 1OC 29K 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOJX ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMSDO BMXJE BPMNR BROTX BRXPI BY8 C45 CAG CGR COF CS3 CUY CVF D-6 D-7 D-E D-F D-I DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS ECF ECM ECT ECV EIF EIHBH EJD EMB EMK EMOBN ENC EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NPM O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 Q~Q R.K RIWAO ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K VVN W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQ9 WQJ WRC WUP WVDHM WXI WXSBR XG1 ZGI ZXP ZZTAW ~IA ~WT |
ID | FETCH-LOGICAL-c4071-33404293549d70f32340233c13ca56aa1f586e5dbabdbad4e5583be7f6ff2d0f2 |
ISSN | 1045-3873 |
IngestDate | Sat Sep 28 08:39:38 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4071-33404293549d70f32340233c13ca56aa1f586e5dbabdbad4e5583be7f6ff2d0f2 |
PMID | 7827712 |
ParticipantIDs | pubmed_primary_7827712 |
PublicationCentury | 1900 |
PublicationDate | September 1994 |
PublicationDateYYYYMMDD | 1994-09-01 |
PublicationDate_xml | – month: 09 year: 1994 text: September 1994 |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of cardiovascular electrophysiology |
PublicationTitleAlternate | J Cardiovasc Electrophysiol |
PublicationYear | 1994 |
SSID | ssj0013605 |
Score | 1.518173 |
Snippet | The hypothesis that levcromakalim, a potassium channel (IK-ATP) activator with antihypertensive properties, has a mechanism-specific antiarrhythmic action... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 731 |
SubjectTerms | Animals Anti-Arrhythmia Agents - therapeutic use Benzopyrans - therapeutic use Cromakalim Dogs Electrocardiography - drug effects Female Heart - drug effects Heart Block - drug therapy Heart Block - physiopathology Hemodynamics - physiology Male Ouabain Pyrroles - therapeutic use Tachycardia, Ventricular - chemically induced Tachycardia, Ventricular - drug therapy Tachycardia, Ventricular - physiopathology Torsades de Pointes - drug therapy Torsades de Pointes - physiopathology |
Title | Mechanism-specific antiarrhythmic effects of the potassium channel activator levcromakalim against repolarization-dependent tachycardias |
URI | https://www.ncbi.nlm.nih.gov/pubmed/7827712 |
Volume | 5 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2loKK-IGipuGsfEC-RUe29OY_l1gopFRIt6lu19u4Si9iJGrdS-AK-ia9jZr1xnIIR8OCV7ZWsZOdoPDs-Z4aQFzZJs9QIFRlnkohLGDRXFnYpI82lTHLt6xSMT-TxGf9wLs4Hgx8d1tJVnb3Kv_1WV_I_VoV7YFdUyf6DZduHwg04B_vCCBaG8a9sPLao2y0WZYSCSST9DGGhCn15OVnWE2S9d-gaXhM1qyFYLq5KL_it7NTX0rjGjfdwaq-Rm6e_QmReDvUXXUDk6L8pwOY3qDWjVc_celjrfLLMPb4WPRFuvsl1DR13fC5lI5n_uaH6jdd51SNM1E-bRsmd_srFPF9YTz84Wmd331pMoM38y-RT0FqYoOvjLU9r5XkhtsRCv6zrmkUHgaOOm1XNm6Pf_SPdI42lQjEmx-x3DJ6mIYZ2cDEvPTAgSFKqIXP_cfJGYe4ws0W2VIq-9QTzRKvvV40it_1Todxt4JD1_Lodsh2eeWOP42Od03vkbjAhPWwQd58MbLVL9g4rwEm5pC_px9aEu2T79erszjjwNPbI91-RSTeRSQMy6cxRQCZtkUkDMmmLTLqBTBqQSfuQSbvIfEDO3r87fXMchZ4fUY6phYgxjiESE3xk1IFjCVwnjOUxy7WQWsdOpNIKk-kMDsOtECnLrHLSucQcuGSf3KpmlX1IqGRGMzdKMyE0F8pkPLbYwQNrJgrJ4kdkv1nki3lT2OUirP7jvoknZGcN3afktgM_Yp9BUFpnz739fwI79JDM |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanism-specific+antiarrhythmic+effects+of+the+potassium+channel+activator+levcromakalim+against+repolarization-dependent+tachycardias&rft.jtitle=Journal+of+cardiovascular+electrophysiology&rft.au=Vos%2C+M+A&rft.au=Gorgels%2C+A+P&rft.au=Lipcsei%2C+G+C&rft.au=De+Groot%2C+S+H&rft.date=1994-09-01&rft.issn=1045-3873&rft.volume=5&rft.issue=9&rft.spage=731&rft_id=info:doi/10.1111%2Fj.1540-8167.1994.tb01196.x&rft_id=info%3Apmid%2F7827712&rft_id=info%3Apmid%2F7827712&rft.externalDocID=7827712 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1045-3873&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1045-3873&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1045-3873&client=summon |